Viewing nowGabamed Capsule 50mg (Pregabalin)
Pregabalin 50mg
Hard capsule · Prescription medication
NBK Pharmaceuticals Co., Ltd.

MFDS item code 202000453 · Approved 2020.01.29 · Insurance code 054800640
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used to treat peripheral and central neuropathic pain in adults. Additionally, it is effective as an adjunct for partial seizures in epilepsy, regardless of whether secondary generalized symptoms are present. It also helps alleviate the symptoms of fibromyalgia. This medication shows promising therapeutic effects in various neurological-related disorders.
This medicine is administered orally as the total daily dose of pregabalin divided into 2 doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and may be increased to 150 mg twice daily (300 mg/day) within 1 week based on efficacy and tolerability. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. [Table 1] Pregabalin dosing based on renal function ≥60: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30-<60: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15-<30: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Starting dose 25 mg, maximum dose 100 mg, single dose TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the method of administration. b: Supplemental dose refers to a dose administered as a single additional dose. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after every 4 hours of hemodialysis. 6. Patients with hepatic impairment No dose adjustment is required in patients with hepatic impairment. 8. Elderly patients (aged 65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behaviors; therefore, mood changes or depressive symptoms should be closely monitored during use. Patients with hypersensitivity to this medication or specific genetic metabolic disorders should not use it. Diabetic patients should be cautious as weight gain may require adjustments in blood sugar control medications. If allergic reactions such as angioedema occur, discontinue use immediately. Elderly patients may be at risk of falls due to side effects like dizziness or drowsiness, so extra caution is needed, especially during the initial phase of treatment. There may be visual blurring or changes in vision; if such symptoms occur, consult with healthcare professionals. Sudden discontinuation of this medication may result in withdrawal symptoms such as insomnia, headache, and anxiety; therefore, gradual tapering according to a physician's instructions is necessary. The risk of drug abuse exists, especially for patients with a history of mental disorders or drug abuse, who require special caution. Patients with impaired kidney function may need dose adjustments for this medication. Patients with severe heart conditions should carefully consider the use of this medication. Caution is warranted when used with other medications that have central nervous system depressant effects due to the risk of respiratory depression. During early pregnancy, there is a risk of fetal malformations; therefore, women of childbearing age should use effective contraception while using this medication. This medication can be transmitted through breast milk, so considerations should be made to either discontinue breastfeeding or the medication. Dizziness and drowsiness may occur while driving or operating machinery; caution is advised. In case of overdose, symptoms such as confusion, drowsiness, or depression may occur; immediate medical attention is required. Keep this medication out of the reach of children and do not transfer it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture, preferably at room temperature between 15 to 30 degrees Celsius. Proper storage will help maintain the efficacy of the medication and ensure safe use.
A hard capsule with a white powder, blue upper part and a white lower part.
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 50mg
Hard capsule · Prescription medication
NBK Pharmaceuticals Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.